JACI-D-23-00956-Figure 4

Your Diagram Title Directed or undirected cell depletion, function or proliferation inhibition → MMF (mycophenolate mofetil): 3 Anti-inflammatory drugs → Anti-IL-(interleukin-)12/-23/-IL-17/-18-directed therapies: 3 Directed or undirected cell depletion, function or proliferation inhibition → Glucocorticosteroids: 2 Directed or undirected cell depletion, function or proliferation inhibition → Rituximab: 2 Checkpoint / Treg augmentation → Abatacept, belatacept: 2 Checkpoint / Treg augmentation → Rapamycin: 2 Directed signaling pathway inhibition → Rapamycin: 2 Directed signaling pathway inhibition → Ruxolitinib, baricitinib, tofacitinib: 2 Anti-inflammatory drugs → Glucocorticosteroids: 2 TCR-signalosome insufficiency → LAT: 1 TCR-signalosome insufficiency → SLP76: 1 V(D)J-recombination insufficiency → RAG1,2: 1 V(D)J-recombination insufficiency → DCLRE1C: 1 V(D)J-recombination insufficiency → PRKCD: 1 AIRE-expression insufficiency → PRKCD: 1 V(D)J-recombination insufficiency → NHEJ1: 1 V(D)J-recombination insufficiency → LIG4: 1 Purine metabolism insufficiency → ADA: 1 CD40:CD40L-signaling insufficiency → CD40LG: 1 T:B-cell co-signaling insufficiency → CD40LG: 1 ICOS:ICOSL-signaling insufficiency → ICOS: 1 T:B-cell co-signaling insufficiency → ICOS: 1 TCR-complex insufficiency → CD3G: 1 TCR-signalosome insufficiency → ZAP70: 1 TCR-signalosome insufficiency → ZAP70/HM-GOF: 1 Transcription factor insufficiency → IKZF2: 1 Actin-cytoskeleton insufficiency → DOCK8: 1 Hippo-signaling insufficiency → STK4: 1 TCR-complex insufficiency → TRAC: 1 TCR-signalosome insufficiency → LCK: 1 TCR-signalosome insufficiency → ITK: 1 CBM-signalosome insufficiency → MALT1: 1 CBM-signalosome insufficiency → CARD11: 1 NFKB1-signaling imbalance → IKBKB-LOF: 1 NFKB1-signaling imbalance → IKBKB-GOF: 1 NFKB2-signaling imbalance → CHUK: 1 AIRE-expression insufficiency → CHUK: 1 NFKB2-signaling imbalance → MAP3K14: 1 AIRE-expression insufficiency → MAP3K14: 1 NFKB2-signaling imbalance → RELB: 1 AIRE-expression insufficiency → RELB: 1 Actin-cytoskeleton insufficiency → MSN: 1 Transferrin uptake insufficiency → TFRC: 1 TCR- and BCR-signalosome insufficiency → SASH3: 1 Actin-cytoskeleton insufficiency → WAS: 1 Actin-cytoskeleton insufficiency → WIPF1: 1 Actin-cytoskeleton insufficiency → ARPCB1: 1 DNA-damage sensing insufficiency → ATM: 1 DNA-methylation insufficiency → DNMT3B: 1 DNA-replication insufficiency → POLE2: 1 Transcription factor insufficiency → Del22q11.2, TBX1: 1 Transcription factor insufficiency → FOXN1: 1 Contiguous gene syndrome → Del11q23del: 1 Mitochondrial RNA-metabolism insufficiency → RMRP: 1 Replication fork DNA-reannealing insufficiency → SMARCAL1: 1 JAK/STAT/SOCS-signaling imbalance → STAT3-DN: 1 Glycosylation insufficiency → PGM3: 1 Folate cycle insufficiency → MTHFD1: 1 Store-operated calcium-entry insufficiency → ORAI1: 1 Store-operated calcium-entry insufficiency → STIM1: 1 Purine metabolism insufficiency → PNP: 1 TLR7-ligand availability imbalance → PNP: 1 IL-2-signalling imbalance → STAT5B: 1 Histone-methylation imbalance → KMT2D: 1 Histone-methylation imbalance → KDM6A: 1 PIP3-signalling imbalance → PIK3CD: 1 PIP3-signalling imbalance → PIK3R1: 1 PIP3-signalling imbalance → PTEN: 1 B-cell co-receptor-signaling insufficiency → CD19: 1 B-cell co-receptor-signaling insufficiency → CD81: 1 BAFF/APRIL/BLYS:TACI-signaling insufficiency → TNFRSF13B: 1 B-cell co-signaling insufficiency → TNFRSF13B: 1 TWEAK:TWEAKR-signaling insufficiency → TNFSF12: 1 T:B-cell co-signaling insufficiency → TNFSF12: 1 NFKB1-signaling imbalance → NFKB1: 1 NFKB2-signaling imbalance → NFKB2: 1 AIRE-expression insufficiency → NFKB2: 1 Transcription factor insufficiency → IKZF1: 1 Transcriptional co-factor insufficiency → IRF2BP2: 1 Actin-cytoskeleton insufficiency → ARHGEF1: 1 Actin-cytoskeleton insufficiency → RAC2: 1 PIP3-signalling imbalance → PIK3CG: 1 Class-switch-recombination and somatic hypermutation insufficiency → AICDA: 1 Class-switch-recombination and somatic hypermutation insufficiency → UNG: 1 Class-switch-recombination and somatic hypermutation insufficiency → CTNNBL1: 1 BAFF/APRIL/BLYS:TACI-signaling insufficiency → TNFSF13: 1 B-cell co-signaling insufficiency → TNFSF13: 1 CBM-signalosome insufficiency → CARD11-GOF: 1 Transcription factor insufficiency → FOXP3: 1 IL-2-signalling imbalance → IL2RA,B: 1 CTLA4-insufficiency → CTLA4: 1 CTLA4-insufficiency → LRBA: 1 CTLA4-insufficiency → DEF6: 1 JAK/STAT/SOCS-signaling imbalance → STAT3-GOF: 1 Transcription factor insufficiency → BACH2: 1 AIRE-expression insufficiency → AIRE: 1 Ubiquitination-insufficiency → ITCH: 1 Protein homeostasis-insufficiency → TPP2: 1 JAK/STAT/SOCS-signaling imbalance → JAK1: 1 Collagen homeostasis-insufficiency → PEPD: 1 JAK/STAT/SOCS-signaling imbalance → SOCS1: 1 PDCD1LG1/PDCD1LG2: PDCD1-signaling insufficiency → PDCD1: 1 FASL:FAS-signaling insufficiency → FAS, FASL: 1 FASL:FAS- and TNF:TNFR-signaling insufficiency → CASP10: 1 FASL:FAS-, TNF:TNFR- and RIPK1-signaling insufficiency → CASP8: 1 FASL:FAS- and TNF:TNFR-signaling insufficiency → FADD: 1 DNA-methylation insufficiency → TET2: 1 FASL:FAS-signaling insufficiency → TET2: 1 Mitochondrial glucose utilization insufficiency → G6PC3: 1 Mitochondrial glucose utilization insufficiency → G6PT1: 1 NADPH-oxidase insufficiency → CYBB, CYBA, NCF1, NCF2: 1 IL-1-family imbalance → CYBB, CYBA, NCF1, NCF2: 1 Complement tagging insufficiency → C1QA, B, C: 1 Complement tagging insufficiency → C4A, B: 1 Complement tagging insufficiency → C2: 1 Complement tagging insufficiency → C3: 1 LAT → HCT: 1 SLP76 → HCT: 1 RAG1,2 → HCT: 1 RAG1,2 → GT: 1 DCLRE1C → HCT: 1 DCLRE1C → GT: 1 PRKCD → HCT: 1 PRKCD → Directed or undirected cell depletion, function or proliferation inhibition: 1 NHEJ1 → HCT: 1 LIG4 → HCT: 1 ADA → Substrate/enzyme replacement therapy: 1 ADA → HCT: 1 ADA → GT: 1 CD40LG → HCT: 1 CD40LG → HCT: 1 ICOS → Directed or undirected cell depletion, function or proliferation inhibition: 1 ICOS → HCT: 1 CD3G → HCT: 1 ZAP70 → HCT: 1 ZAP70/HM-GOF → HCT: 1 IKZF2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 IKZF2 → HCT: 1 DOCK8 → HCT: 1 STK4 → HCT: 1 TRAC → HCT: 1 LCK → HCT: 1 ITK → HCT: 1 MALT1 → HCT: 1 CARD11 → HCT: 1 IKBKB-LOF → HCT: 1 IKBKB-GOF → Directed or undirected cell depletion, function or proliferation inhibition: 1 CHUK → HCT: 1 CHUK → Directed or undirected cell depletion, function or proliferation inhibition: 1 MAP3K14 → HCT: 1 MAP3K14 → Directed or undirected cell depletion, function or proliferation inhibition: 1 RELB → HCT: 1 RELB → Directed or undirected cell depletion, function or proliferation inhibition: 1 MSN → Directed or undirected cell depletion, function or proliferation inhibition: 1 MSN → HCT: 1 TFRC → Directed or undirected cell depletion, function or proliferation inhibition: 1 TFRC → HCT: 1 SASH3 → Directed or undirected cell depletion, function or proliferation inhibition: 1 SASH3 → HCT: 1 WAS → HCT: 1 WAS → GT: 1 WIPF1 → HCT: 1 ARPCB1 → HCT: 1 ATM → Directed or undirected cell depletion, function or proliferation inhibition: 1 ATM → HCT: 1 DNMT3B → Directed or undirected cell depletion, function or proliferation inhibition: 1 DNMT3B → HCT: 1 POLE2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 Del22q11.2, TBX1 → Thymus transplantation: 1 FOXN1 → Thymus transplantation: 1 Del11q23del → Directed or undirected cell depletion, function or proliferation inhibition: 1 Del11q23del → Thymus transplantation: 1 RMRP → Directed or undirected cell depletion, function or proliferation inhibition: 1 RMRP → HCT: 1 SMARCAL1 → Directed or undirected cell depletion, function or proliferation inhibition: 1 SMARCAL1 → HCT: 1 STAT3-DN → Anti-inflammatory drugs: 1 STAT3-DN → HCT: 1 PGM3 → Directed or undirected cell depletion, function or proliferation inhibition: 1 PGM3 → HCT: 1 MTHFD1 → Substrate/enzyme replacement therapy: 1 ORAI1 → HCT: 1 STIM1 → HCT: 1 PNP → Substrate/enzyme replacement therapy: 1 PNP → HCT: 1 PNP → GT: 1 STAT5B → Directed or undirected cell depletion, function or proliferation inhibition: 1 STAT5B → HCT: 1 KMT2D → Directed or undirected cell depletion, function or proliferation inhibition: 1 KDM6A → Directed or undirected cell depletion, function or proliferation inhibition: 1 PIK3CD → Directed signaling pathway inhibition: 1 PIK3CD → HCT: 1 PIK3R1 → Directed signaling pathway inhibition: 1 PIK3R1 → HCT: 1 PTEN → Directed signaling pathway inhibition: 1 CD19 → Directed or undirected cell depletion, function or proliferation inhibition: 1 CD81 → Directed or undirected cell depletion, function or proliferation inhibition: 1 TNFRSF13B → Directed or undirected cell depletion, function or proliferation inhibition: 1 TNFRSF13B → Directed or undirected cell depletion, function or proliferation inhibition: 1 TNFSF12 → Directed or undirected cell depletion, function or proliferation inhibition: 1 TNFSF12 → Directed or undirected cell depletion, function or proliferation inhibition: 1 NFKB1 → Directed or undirected cell depletion, function or proliferation inhibition: 1 NFKB1 → Anti-inflammatory drugs: 1 NFKB1 → HCT: 1 NFKB2 → HCT: 1 NFKB2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 IKZF1 → Directed or undirected cell depletion, function or proliferation inhibition: 1 IKZF1 → HCT: 1 IRF2BP2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 IRF2BP2 → Anti-inflammatory drugs: 1 ARHGEF1 → Directed or undirected cell depletion, function or proliferation inhibition: 1 RAC2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 PIK3CG → Directed signaling pathway inhibition: 1 PIK3CG → Directed or undirected cell depletion, function or proliferation inhibition: 1 AICDA → Directed or undirected cell depletion, function or proliferation inhibition: 1 UNG → Directed or undirected cell depletion, function or proliferation inhibition: 1 CTNNBL1 → Directed or undirected cell depletion, function or proliferation inhibition: 1 TNFSF13 → Directed or undirected cell depletion, function or proliferation inhibition: 1 TNFSF13 → Directed or undirected cell depletion, function or proliferation inhibition: 1 CARD11-GOF → Directed or undirected cell depletion, function or proliferation inhibition: 1 FOXP3 → HCT: 1 FOXP3 → Checkpoint / Treg augmentation: 1 FOXP3 → Directed or undirected cell depletion, function or proliferation inhibition: 1 IL2RA,B → HCT: 1 IL2RA,B → Checkpoint / Treg augmentation: 1 IL2RA,B → Directed or undirected cell depletion, function or proliferation inhibition: 1 CTLA4 → HCT: 1 CTLA4 → Checkpoint / Treg augmentation: 1 LRBA → HCT: 1 LRBA → Checkpoint / Treg augmentation: 1 DEF6 → HCT: 1 DEF6 → Checkpoint / Treg augmentation: 1 STAT3-GOF → Directed signaling pathway inhibition: 1 STAT3-GOF → Anti-inflammatory drugs: 1 BACH2 → Checkpoint / Treg augmentation: 1 BACH2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 BACH2 → Anti-inflammatory drugs: 1 AIRE → Checkpoint / Treg augmentation: 1 AIRE → Directed or undirected cell depletion, function or proliferation inhibition: 1 ITCH → Checkpoint / Treg augmentation: 1 ITCH → Directed or undirected cell depletion, function or proliferation inhibition: 1 TPP2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 TPP2 → HCT: 1 JAK1 → Directed signaling pathway inhibition: 1 JAK1 → Anti-inflammatory drugs: 1 PEPD → Directed or undirected cell depletion, function or proliferation inhibition: 1 PEPD → Anti-inflammatory drugs: 1 SOCS1 → Directed signaling pathway inhibition: 1 SOCS1 → Anti-inflammatory drugs: 1 PDCD1 → Directed or undirected cell depletion, function or proliferation inhibition: 1 FAS, FASL → Directed signaling pathway inhibition: 1 CASP10 → Directed signaling pathway inhibition: 1 CASP8 → Directed signaling pathway inhibition: 1 CASP8 → Directed or undirected cell depletion, function or proliferation inhibition: 1 CASP8 → HCT: 1 FADD → Directed signaling pathway inhibition: 1 FADD → Directed or undirected cell depletion, function or proliferation inhibition: 1 FADD → HCT: 1 TET2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 TET2 → Directed signaling pathway inhibition: 1 TET2 → HCT: 1 G6PC3 → Directed signaling pathway inhibition: 1 G6PT1 → Directed signaling pathway inhibition: 1 CYBB, CYBA, NCF1, NCF2 → HCT: 1 CYBB, CYBA, NCF1, NCF2 → GT: 1 CYBB, CYBA, NCF1, NCF2 → Anti-inflammatory drugs: 1 C1QA, B, C → Directed signaling pathway inhibition: 1 C1QA, B, C → Directed or undirected cell depletion, function or proliferation inhibition: 1 C1QA, B, C → Anti-inflammatory drugs: 1 C4A, B → Directed signaling pathway inhibition: 1 C4A, B → Directed or undirected cell depletion, function or proliferation inhibition: 1 C4A, B → Anti-inflammatory drugs: 1 C2 → Directed signaling pathway inhibition: 1 C2 → Directed or undirected cell depletion, function or proliferation inhibition: 1 C2 → Anti-inflammatory drugs: 1 C3 → Directed signaling pathway inhibition: 1 C3 → Directed or undirected cell depletion, function or proliferation inhibition: 1 C3 → Anti-inflammatory drugs: 1 Directed or undirected cell depletion, function or proliferation inhibition → CAAR- (chimeric autoantibody receptor-) T cells: 1 Directed or undirected cell depletion, function or proliferation inhibition → Daratumumab: 1 Directed or undirected cell depletion, function or proliferation inhibition → Belimumab: 1 Directed or undirected cell depletion, function or proliferation inhibition → Epratuzumab: 1 Directed or undirected cell depletion, function or proliferation inhibition → Ibrutinib: 1 Directed or undirected cell depletion, function or proliferation inhibition → Blinatumomab: 1 Directed or undirected cell depletion, function or proliferation inhibition → Inebilizumab: 1 Directed or undirected cell depletion, function or proliferation inhibition → Alemtuzumab: 1 Directed or undirected cell depletion, function or proliferation inhibition → ATG (anti-thymocyte globulin): 1 Directed or undirected cell depletion, function or proliferation inhibition → AZT (azathioprine): 1 Directed or undirected cell depletion, function or proliferation inhibition → Vbl (vinblastine): 1 Directed or undirected cell depletion, function or proliferation inhibition → CY (cyclophosphamide): 1 Directed or undirected cell depletion, function or proliferation inhibition → VP16 (etoposide): 1 Directed or undirected cell depletion, function or proliferation inhibition → CyA (cyclosporin A): 1 Directed or undirected cell depletion, function or proliferation inhibition → Bortezomib, Carfilzomib: 1 Directed or undirected cell depletion, function or proliferation inhibition → Lenalidomid, thalidomide: 1 Checkpoint / Treg augmentation → Low-dose aldesleukin: 1 Checkpoint / Treg augmentation → CAR-Tregs: 1 Directed signaling pathway inhibition → Fostamatinib: 1 Directed signaling pathway inhibition → Idelalisib: 1 Directed signaling pathway inhibition → Leniosilib: 1 Directed signaling pathway inhibition → Hydroxychloroquine: 1 Anti-inflammatory drugs → Anakinra: 1 Anti-inflammatory drugs → Tocilizumab: 1 Anti-inflammatory drugs → Anti-TNF: 1 Anti-inflammatory drugs → Anti-IFN: 1 Anti-inflammatory drugs → Anifrolumab: 1 TCR-signalosome insufficiency: 6 LAT: 1 SLP76: 1 V(D)J-recombination insufficiency: 5 RAG1,2: 2 DCLRE1C: 2 PRKCD: 2 AIRE-expression insufficiency: 6 NHEJ1: 1 LIG4: 1 Purine metabolism insufficiency: 2 ADA: 3 CD40:CD40L-signaling insufficiency: 1 CD40LG: 2 T:B-cell co-signaling insufficiency: 3 ICOS:ICOSL-signaling insufficiency: 1 ICOS: 2 TCR-complex insufficiency: 2 CD3G: 1 ZAP70: 1 ZAP70/HM-GOF: 1 Transcription factor insufficiency: 6 IKZF2: 2 Actin-cytoskeleton insufficiency: 7 DOCK8: 1 Hippo-signaling insufficiency: 1 STK4: 1 TRAC: 1 LCK: 1 ITK: 1 CBM-signalosome insufficiency: 3 MALT1: 1 CARD11: 1 NFKB1-signaling imbalance: 3 IKBKB-LOF: 1 IKBKB-GOF: 1 NFKB2-signaling imbalance: 4 CHUK: 2 MAP3K14: 2 RELB: 2 MSN: 2 Transferrin uptake insufficiency: 1 TFRC: 2 TCR- and BCR-signalosome insufficiency: 1 SASH3: 2 WAS: 2 WIPF1: 1 ARPCB1: 1 DNA-damage sensing insufficiency: 1 ATM: 2 DNA-methylation insufficiency: 2 DNMT3B: 2 DNA-replication insufficiency: 1 POLE2: 1 Del22q11.2, TBX1: 1 FOXN1: 1 Contiguous gene syndrome: 1 Del11q23del: 2 Mitochondrial RNA-metabolism insufficiency: 1 RMRP: 2 Replication fork DNA-reannealing insufficiency: 1 SMARCAL1: 2 JAK/STAT/SOCS-signaling imbalance: 4 STAT3-DN: 2 Glycosylation insufficiency: 1 PGM3: 2 Folate cycle insufficiency: 1 MTHFD1: 1 Store-operated calcium-entry insufficiency: 2 ORAI1: 1 STIM1: 1 PNP: 3 TLR7-ligand availability imbalance: 1 IL-2-signalling imbalance: 2 STAT5B: 2 Histone-methylation imbalance: 2 KMT2D: 1 KDM6A: 1 PIP3-signalling imbalance: 4 PIK3CD: 2 PIK3R1: 2 PTEN: 1 B-cell co-receptor-signaling insufficiency: 2 CD19: 1 CD81: 1 BAFF/APRIL/BLYS:TACI-signaling insufficiency: 2 TNFRSF13B: 2 B-cell co-signaling insufficiency: 2 TWEAK:TWEAKR-signaling insufficiency: 1 TNFSF12: 2 NFKB1: 3 NFKB2: 2 IKZF1: 2 Transcriptional co-factor insufficiency: 1 IRF2BP2: 2 ARHGEF1: 1 RAC2: 1 PIK3CG: 2 Class-switch-recombination and somatic hypermutation insufficiency: 3 AICDA: 1 UNG: 1 CTNNBL1: 1 TNFSF13: 2 CARD11-GOF: 1 FOXP3: 3 IL2RA,B: 3 CTLA4-insufficiency: 3 CTLA4: 2 LRBA: 2 DEF6: 2 STAT3-GOF: 2 BACH2: 3 AIRE: 2 Ubiquitination-insufficiency: 1 ITCH: 2 Protein homeostasis-insufficiency: 1 TPP2: 2 JAK1: 2 Collagen homeostasis-insufficiency: 1 PEPD: 2 SOCS1: 2 PDCD1LG1/PDCD1LG2: PDCD1-signaling insufficiency: 1 PDCD1: 1 FASL:FAS-signaling insufficiency: 2 FAS, FASL: 1 FASL:FAS- and TNF:TNFR-signaling insufficiency: 2 CASP10: 1 FASL:FAS-, TNF:TNFR- and RIPK1-signaling insufficiency: 1 CASP8: 3 FADD: 3 TET2: 3 Mitochondrial glucose utilization insufficiency: 2 G6PC3: 1 G6PT1: 1 NADPH-oxidase insufficiency: 1 CYBB, CYBA, NCF1, NCF2: 3 IL-1-family imbalance: 1 Complement tagging insufficiency: 4 C1QA, B, C: 3 C4A, B: 3 C2: 3 C3: 3 HCT: 57 GT: 6 Directed or undirected cell depletion, function or proliferation inhibition: 54 Substrate/enzyme replacement therapy: 3 Thymus transplantation: 3 Anti-inflammatory drugs: 13 Directed signaling pathway inhibition: 18 Checkpoint / Treg augmentation: 8 Glucocorticosteroids: 4 Rituximab: 2 CAAR- (chimeric autoantibody receptor-) T cells: 1 Daratumumab: 1 Belimumab: 1 Epratuzumab: 1 Ibrutinib: 1 Blinatumomab: 1 Inebilizumab: 1 Alemtuzumab: 1 ATG (anti-thymocyte globulin): 1 AZT (azathioprine): 1 MMF (mycophenolate mofetil): 3 Vbl (vinblastine): 1 CY (cyclophosphamide): 1 VP16 (etoposide): 1 CyA (cyclosporin A): 1 Bortezomib, Carfilzomib: 1 Lenalidomid, thalidomide: 1 Abatacept, belatacept: 2 Rapamycin: 4 Low-dose aldesleukin: 1 CAR-Tregs: 1 Fostamatinib: 1 Idelalisib: 1 Leniosilib: 1 Ruxolitinib, baricitinib, tofacitinib: 2 Hydroxychloroquine: 1 Anakinra: 1 Tocilizumab: 1 Anti-TNF: 1 Anti-IL-(interleukin-)12/-23/-IL-17/-18-directed therapies: 3 Anti-IFN: 1 Anifrolumab: 1 TCR-signalosome insufficiency LAT SLP76 V(D)J-recombination insufficiency RAG1,2 DCLRE1C PRKCD AIRE-expression insufficiency NHEJ1 LIG4 Purine metabolism insufficiency ADA CD40:CD40L-signaling insufficiency CD40LG T:B-cell co-signaling insufficiency ICOS:ICOSL-signaling insufficiency ICOS TCR-complex insufficiency CD3G ZAP70 ZAP70/HM-GOF Transcription factor insufficiency IKZF2 Actin-cytoskeleton insufficiency DOCK8 Hippo-signaling insufficiency STK4 TRAC LCK ITK CBM-signalosome insufficiency MALT1 CARD11 NFKB1-signaling imbalance IKBKB-LOF IKBKB-GOF NFKB2-signaling imbalance CHUK MAP3K14 RELB MSN Transferrin uptake insufficiency TFRC TCR- and BCR-signalosome insufficiency SASH3 WAS WIPF1 ARPCB1 DNA-damage sensing insufficiency ATM DNA-methylation insufficiency DNMT3B DNA-replication insufficiency POLE2 Del22q11.2, TBX1 FOXN1 Contiguous gene syndrome Del11q23del Mitochondrial RNA-metabolism insufficiency RMRP Replication fork DNA-reannealing insufficiency SMARCAL1 JAK/STAT/SOCS-signaling imbalance STAT3-DN Glycosylation insufficiency PGM3 Folate cycle insufficiency MTHFD1 Store-operated calcium-entry insufficiency ORAI1 STIM1 PNP TLR7-ligand availability imbalance IL-2-signalling imbalance STAT5B Histone-methylation imbalance KMT2D KDM6A PIP3-signalling imbalance PIK3CD PIK3R1 PTEN B-cell co-receptor-signaling insufficiency CD19 CD81 BAFF/APRIL/BLYS:TACI-signaling insufficiency TNFRSF13B B-cell co-signaling insufficiency TWEAK:TWEAKR-signaling insufficiency TNFSF12 NFKB1 NFKB2 IKZF1 Transcriptional co-factor insufficiency IRF2BP2 ARHGEF1 RAC2 PIK3CG Class-switch-recombination and somatic hypermutation insufficiency AICDA UNG CTNNBL1 TNFSF13 CARD11-GOF FOXP3 IL2RA,B CTLA4-insufficiency CTLA4 LRBA DEF6 STAT3-GOF BACH2 AIRE Ubiquitination-insufficiency ITCH Protein homeostasis-insufficiency TPP2 JAK1 Collagen homeostasis-insufficiency PEPD SOCS1 PDCD1LG1/PDCD1LG2: PDCD1-signaling insufficiency PDCD1 FASL:FAS-signaling insufficiency FAS, FASL FASL:FAS- and TNF:TNFR-signaling insufficiency CASP10 FASL:FAS-, TNF:TNFR- and RIPK1-signaling insufficiency CASP8 FADD TET2 Mitochondrial glucose utilization insufficiency G6PC3 G6PT1 NADPH-oxidase insufficiency CYBB, CYBA, NCF1, NCF2 IL-1-family imbalance Complement tagging insufficiency C1QA, B, C C4A, B C2 C3 HCT GT Directed or undirected cell depletion, function or proliferation inhibition Substrate/enzyme replacement therapy Thymus transplantation Anti-inflammatory drugs Directed signaling pathway inhibition Checkpoint / Treg augmentation Glucocorticosteroids Rituximab CAAR- (chimeric autoantibody receptor-) T cells Daratumumab Belimumab Epratuzumab Ibrutinib Blinatumomab Inebilizumab Alemtuzumab ATG (anti-thymocyte globulin) AZT (azathioprine) MMF (mycophenolate mofetil) Vbl (vinblastine) CY (cyclophosphamide) VP16 (etoposide) CyA (cyclosporin A) Bortezomib, Carfilzomib Lenalidomid, thalidomide Abatacept, belatacept Rapamycin Low-dose aldesleukin CAR-Tregs Fostamatinib Idelalisib Leniosilib Ruxolitinib, baricitinib, tofacitinib Hydroxychloroquine Anakinra Tocilizumab Anti-TNF Anti-IL-(interleukin-)12/-23/-IL-17/-18-directed therapies Anti-IFN Anifrolumab